Compare SELF & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SELF | RNTX |
|---|---|---|
| Founded | 1983 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.1M | 65.3M |
| IPO Year | 1997 | 2017 |
| Metric | SELF | RNTX |
|---|---|---|
| Price | $5.52 | $0.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $10.00 |
| AVG Volume (30 Days) | 29.1K | ★ 486.3K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | N/A | ★ 44.16 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $12,705,245.00 | N/A |
| Revenue This Year | $3.04 | N/A |
| Revenue Next Year | $3.47 | N/A |
| P/E Ratio | $50.45 | ★ N/A |
| Revenue Growth | ★ 1.40 | N/A |
| 52 Week Low | $4.73 | $0.69 |
| 52 Week High | $5.63 | $2.18 |
| Indicator | SELF | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.00 | 48.41 |
| Support Level | $4.99 | $0.69 |
| Resistance Level | $5.63 | $1.05 |
| Average True Range (ATR) | 0.16 | 0.07 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 71.69 | 63.28 |
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.